The FDA has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.
Zacks Investment Research on MSN
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Shares of Ovid Therapeutics OVID rallied 39.2% primarily driven by the encouraging top-line data readout from an early-stage ...
“Future research will help clarify whether long-term music practice can strengthen the brain’s ability to process rhythm ...
Age-related differences in cortical aperiodic signals can be driven by cardiac influences, emphasizing the need to control for cardiac contributions in studies interpreting cortically measured ...
Researchers say the experimental tool has huge implications for public health, especially in conjunction with Alzheimer’s ...
ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct ...
A Simon Fraser University-led clinical research study is evaluating how advanced brain imaging could improve epilepsy surgery in British Columbia. Epilepsy affects more than 50,000 people in B.C., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback